Supplier Review
Reviewed March 19, 2026
Is ScinoPharm legit?
The buyer-side answer is that ScinoPharm presents itself as a serious pharmaceutical manufacturing company with peptide CDMO capability,
but buyers still need to verify whether the quoted material fits the exact entity, site, and scope described publicly.
Public claims reviewed
- ScinoPharm Taiwan says it is a pharmaceutical company focused on API and drug product development and manufacturing.
- ScinoPharm publicly says it operates FDA- and cGMP-compliant facilities.
- Its CDMO page says it has more than 20 years of peptide synthesis and API development expertise and 300+ completed CDMO projects.
- ScinoPharm positions itself as serving U.S. and European markets with integrated manufacturing support.
Source pages reviewed March 19, 2026:
ScinoPharm company page,
ScinoPharm CDMO services.
What a buyer should verify next
- Which legal entity and site would actually handle the peptide scope you are sourcing.
- Whether the peptide-related claims apply directly to the quoted material or reflect broader CDMO capability.
- Whether the documentation package, COA path, and commercial paperwork align with that entity and site.
- Whether the public cGMP and regulatory language is relevant to your exact procurement use case.
When a paid screen is justified
- You are comparing ScinoPharm to China-linked or lower-cost Asia alternatives and need a clearer diligence basis.
- The order value is meaningful enough that entity, site, or quality-scope ambiguity matters.
- You need to distinguish broad pharma manufacturing credibility from the exact peptide sourcing path for your order.
APV view
ScinoPharm appears to have a credible public pharma manufacturing profile, but buyers should still verify the exact entity,
site, peptide scope, and document path relevant to their order before relying on that profile for qualification.